Skip to main content
Terug
Watch Compare

Transcode Therapeutics, Inc.

Datakwaliteit: 83%
RNAZ
Nasdaq Manufacturing Chemicals
€ 8,57
▲ € 0,21 (2,49%)
Marktkapitalisatie: 7,86 M
Prijs
€ 8,57
Marktkapitalisatie
7,86 M
Dagbereik
€ 8,22 — € 8,57
52-Weeksbereik
€ 6,08 — € 22,04
Volume
2.829
Openen € 8,30
50D / 200D Gem.
€ 9,59
10,62% below
50D / 200D Gem.
€ 9,89
13,39% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -14,54 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-716,53%
Onder sectorgemiddelde (-53,47%)
ROIC-300,58%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio1,60
Interest Coverage-2156,07

Waardering

PE (TTM)
-0,29
Boven sectorgemiddelde (-1,47)
P/B Ratio5,51
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,3 -1,5
P/B 5,5 1,6
ROE % -716,5 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -27,13 M
ROE -716,53% ROA -402,19%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14,54 M
ROIC -300,58% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,60
Interest Coverage -2156,07 Asset Turnover N/A
Working Capital 1,78 M Tangible Book Value 1,43 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,29 Forward P/E N/A
P/B Ratio 5,51 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -185,09%
Market Cap 7,86 M Enterprise Value 5,02 M
Per Share
EPS (Diluted TTM) -80,42 Revenue / Share N/A
FCF / Share -15,86 OCF / Share -15,83
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 53,59%
SBC-Adj. FCF -16,29 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021
Revenue — — — —
Net Income -16,75 M -18,55 M -17,56 M -6,84 M
EPS (Diluted) -47,14 -103,61 -1,35 -0,81
Gross Profit — — — —
Operating Income -15,66 M -19,42 M -18,67 M -6,15 M
EBITDA — — — —
R&D Expenses 9,71 M 12,26 M 10,23 M 2,75 M
SG&A Expenses — — — —
D&A 90.894,0 123.483,0 98.606,0 42.470,0
Interest Expense 26.813,0 55.899,0 95.070,0 95.070,0
Income Tax 0,0 0,0 0,0 53.051,0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021
Total Assets 7,29 M 5,17 M 7,59 M 22,94 M
Total Liabilities 9,31 M 3,53 M 4,35 M 2,53 M
Shareholders' Equity -2,02 M 1,64 M 3,24 M 20,40 M
Total Debt — — — —
Cash & Equivalents 5,81 M 2,77 M 4,97 M 20,83 M
Current Assets 7,09 M 4,46 M 7,38 M 22,73 M
Current Liabilities 2,77 M 3,49 M 4,35 M 2,53 M